ESMO Congress 2026

Breast cancer is the most common cancer diagnosis among women, with approximately 2.3 million new cases annually worldwide ^[1]; after diagnosis, patients commonly turn to the internet for information or reassurance, despite the risk of low-quality or even incorrect content, and Facebook is a source of health-related information for 40% of English-speaking and 60% of Spanish-speaking adults in the United States ^[1]. Prior research applied natural language processing methods such as BERTopic to 243,029 English-language and 96,334 Spanish-language posts, noting that Spanish-language breast cancer content had been less studied ^[1]. This background directly serves the reading of the current posts: the breast cancer information ecosystem for Spanish-speaking audiences relies heavily on social media, and how congress content enters this ecosystem is itself an observation point.

There were two live posts this time, both in Spanish. @asammavitoria posted with the #ASAMMA tag, stating that research advances and hope does too, described ESMO 2026 as the largest oncology congress in Europe, and offered a goal-style statement—reconnect science with the fact that we are talking about human beings; @SOG_Galicia merely tagged #Cancerdemama en #ESMO26 to mark the presence of breast cancer topics. Neither post mentioned any trial name, endpoint, or efficacy figures; specific breast cancer readouts at this congress were not disclosed and await confirmation from subsequent materials, and the only content explicitly stated in the posts is the congress positioning and this humanistic statement.

Compared with existing knowledge, the confirmed step forward lies at the communication level rather than the clinical evidence level. The background literature established that Spanish-language breast cancer discussion exists massively on social media and that audiences rely heavily on such channels ^[1]; these two live posts show that congress information entered social platforms directly in Spanish via the above accounts, framing the breast cancer topic in humanistic terms. However, ^[1] is a communication and information-science study containing no efficacy data, and the live posts likewise contain no data, so there are no comparable clinical facts between the two sides, and the claim that research advances has no verifiable numerical support within the current materials.

Finally, the limitations: the live posts contain no trial identifiers, endpoints, or sample sizes, and any specific readouts remain to be confirmed; the background literature is based on data from the Facebook platform in the United States ^[1], and its explanatory power for congress-floor communication is likewise limited.